"Fight" family bottom style into the Bo show! Roche AZ Pfizer GSK Sanofi collective "drying muscles", who has the strongest family background? 20 "top goods" spoilers in advance

AbbVie: Skyrizi

AbbVie will showcase AbbVie's future "Constellation" program at this year's CIIE, bringing the "China Premiere" of five innovative products in four key areas of immunology, oncology, neurology and ophthalmology:

Skyrizi, a key product of immunology, is a humanized immunoglobulin G1 (lgG1) monoclonal antibody that inhibits its mediated signaling pathway
by selectively binding to the p19 subunit of interleukin-23 (IL-23).
It has been approved for the treatment of psoriasis and psoriatic arthritis
in countries such as Europe, America and Japan.
Indications for Crohn's disease have also been approved
in the United States.
In the next 5 years, several indications in the fields of gastroenterology, dermatology and rheumatology will be approved
worldwide.
Skyrizi has submitted a marketing application for ulcerative colitis to the Chinese drug regulatory authority, which is expected to benefit more Chinese patients
in the future.

Allergan Aesthetics: Cool Sculpting ®

Allergan Aesthetics, a global medical cosmetology biopharmaceutical company, will showcase Diamond Glow®, a skin care device and functional skin care product Skin, which are not yet on the market in China Medica®, exhibited classic products including botulinum toxin botulinum toxin Botox ®, the world's production and sales of 100 million units of the leading hyaluronic acid brand Joe Arden ® approved series in China, and the newly upgraded cool plastic ® non-invasive cryofat reduction device
。 Among them, the Joyaden series includes the first to enter China for the ultimate and elegant ®, China's first approved hyaluronic acid filler for cheek indications Qiao Yaden ® ® Plump XC, China's only hyaluronic acid product ® approved for lip injection, Juvéderm®Volux® for improving chin and jaw facial volume that can only be used in Hainan Lecheng pilot area in China, and filling the domestic cross-linked hyaluronic acid to improve facial and neck fine lines, ® Juvéderm®VoliteTM
that also improves the gap in the skin market.

Alcon: Precision ™ 1

LIGHT-CLEAR DAY-TO-THROW ™ IS THE FIRST CONTACT LENS TO APPLY ALCON'S PATENTED INNOVATIVE SMARTSURFACE™ ™ TECHNOLOGY, PROVIDING LONG-LASTING HYDRATION AND A GOOD VISUAL EXPERIENCE
FOR USERS WHO NEED TO WEAR IT FOR A LONG TIME.
Verofilcon is used in this product A new generation of silicone hydrogel material, so that it can achieve high oxygen permeability, meet the oxygen demand of the cornea, and care for eye health
.
SMARTSURFACE™ ™ is a lens surface treatment technology based on layered water-containing technology, which can make the surface water content of the lens reach 80%, bringing long-lasting wetness and comfortable touch
that traditional silicone hydrogels cannot have.
Not only that, the light day ™ throw is also a class of anti-UV products certified by the International Organization for Standardization, adding a health shield to the eyes to resist ultraviolet rays
.

Bayer: Vitekai ® (lalotinib)

Larotinib is a major advance
in cancer treatment as the first treatment specifically designed specifically for adult and pediatric patients with TRK fusion tumors, targeting drivers of tumor spread and growth rather than the primary site of the tumor.
The approval of Vitekai ® in China provides a new treatment option for TRK fusion tumor patients, leading a new era
of precision tumor therapy.

Boehringer Ingelheim: Pesolimab

It is expected to achieve "simultaneous development and listing in China and the world" of GPP "nemesis" pesolimab
.
The first-in-class immunological new drug spesolimab (generic name: pesolimab injection) for the treatment of the onset of generalized pustular psoriasis (GPP) of a rare skin disease is expected to be approved in China in 2022, almost simultaneously
with the FDA approval (September 2022).
Benefiting from the promotion of the "China Key" project, Pesolimab is the first innovative drug
of Boehringer Ingelheim to participate in early clinical trials in China and achieve global simultaneous registration application.

GlaxoSmithKline: Bivalent HPV vaccine Cirishi

As the first HPV vaccine approved for marketing in China, GSK bivalent HPV vaccine Xirishi will be unveiled again this time, as the first HPV vaccine approved for two-dose vaccination in China, this Expo is also the first exhibition
of its two-dose vaccination procedure for girls aged 9-14 years old.
In addition to innovative products, during the Expo, GSK will invite a number of preventive immunization and clinical experts to visit the booth to popularize knowledge about cervical cancer prevention and HPV vaccines, help the public understand HPV vaccines scientifically, and eliminate "vaccine hesitancy"
.

Pfizer: Talazoparib

Pfizer brought the innovative dual-mechanism PARP inhibitor Talazoparib, a global star product of Pfizer oncology to achieve the Asian premiere
through the Expo stage.
The latest announcement of TALAPRO-2 The Phase III study results demonstrate that Talazoparib is the first PARP inhibitor to be clinically beneficial in patients with metastatic castration against prostate cancer (mCRPC) in combination with enzalutamide, which means that mCRPC patients are no longer limited by genetic testing and will also provide new and promising treatment options
for patients with first-line treatment.

Gilead: Topavi ® (gosastuzumab)

Topavil (gosatuzumab ®) is the world's first and only approved antibody-conjugate drug targeting Trop-2 for the treatment of relapsed or refractory metastatic triple-negative breast cancer targeting the Trop-2 receptor, a cell surface antigen that is overexpressed in many tumor types, including more than 90% of breast and bladder cancers
.
The appearance of Topway at ® the Expo means that Gilead China has begun to enter the field of
oncology.

Contith: MynxGrip blocks the hemostatic system

The revolutionary new generation of vascular closure product is the first in China for the closure of puncture openings for all interventional procedures in the femoral artery
.
It adopts the world's unique and only "balloon plugging" technology, which has the core advantage
of "taking the initiative to stop bleeding and leaving no trace after healing".
Candis is always exploring breakthrough technology for vascular closure, aiming to avoid additional blood transfusion and surgical repair due to puncture complications (such as retroperitoneal hemorrhage, pseudoaneurysm, infected amputation, etc.
), reduce patient pain and financial burden, and safeguard the final step of interventional surgery!

Roche: vepostuzumab (Polivy®)

Vepostuzumab (Polivy®) is the world's first ADC drug (antibody drug conjugate) targeting CD79b, and the experimental data exceeds the gold standard for first-line treatment in the past 20 years, breaking through the "ceiling"
of diffuse large B lymphoma (DLBCL) treatment.
In recurrent or refractory diffuse large B lymphoma (R/R DLBCL) achieved triple patient benefit
.
It will be launched in China soon, benefiting lymphoma patients
in China.

Merck: Assisted reproduction solutions

In the field of assisted reproduction, Merck continues to empower 360° one-stop solutions covering drug treatment, laboratory technology and services through advanced digital technology, from advanced egg freezing technology, controlled ultra-stimulation drugs, luteal support, and improved follicle development to laboratory temperature, humidity, safe light and gas concentration control, and its advanced drugs, technologies and solutions further help improve the success rate of assisted reproductive technology (ART) and make patients undergoing assisted reproduction have a more comfortable treatment experience
。 Currently, around 5 million babies have been born
worldwide with the help of Merck assisted reproduction solutions.

Merck: Monogravir

The oral anti-new coronavirus drug monogravir, jointly developed by Merck and Ridgeback, is the first authorized oral anti-new coronavirus drug, which has obtained marketing authorization or emergency use authorization in more than 40 countries or regions around the world as of the end of August 2022, including the United States, the European Union, Australia, Japan, South Korea, Hong Kong, Taiwan, etc.
Merck has supplied more than 8.
6 million courses of monogravir to more than 30 markets worldwide, treating more than 1.
8 million patients
.
Merck's regulatory applications around the world are being submitted and reviewed
.

Novartis: Pluvicto radioligand therapy

In March 2022, Novartis radioligand therapy Pluvicto received approval from the U.
S.
Food and Drug Administration (FDA) for the treatment of adult patients
with prostate-specific membrane antigen (PSMA)-positive, metastatic castration-resistant prostate cancer (mCRPC).
These patients usually received androgen pathway inhibitors and taxane-based chemotherapy
.

Radioligand Therapy, RLT) is a precision anti-cancer therapy, the principle of which is that radioisotopes bind to targeted molecules (ligands), and after intravenous injection, specifically bind to biomarkers expressed on the surface of target cells (mainly cancer cells), localize tumor lesions throughout the body (such as soft tissues, lymph nodes or bone), emit radiation, kill target cells, and have limited
damage to surrounding healthy tissues.

Novo Nordisk: Digital solutions

Novo Nordisk showcased two digital disease management tools – Novo Nordisk's first digital platform to support services for patients with rare diseases, "Novo Care – Making a Difference", and China's first connectable and transportable smart insulin pen No.
®6
.
Novo Nordisk continues to work with partners to create innovative digital health solutions
for patients through a combination of hardware and software.

Organon: Companion

As the only single-root subcutaneous implant contraceptive product approved in China, Epinon ® is a long-acting reversible contraceptive method that provides women with high-efficiency contraceptive effect
for up to 3 years by implanting progestogen-containing extended-release materials under the skin on the inside of the upper arm.
It officially entered China in 2012, providing Chinese women with a "fertility-friendly" contraceptive option
.

JOHNSON & JOHNSON MEDICAL SCIENCE: VARIPULSE® MAGNETOPOSITIONING MULTICHANNEL PULSE ABLATION CATHETER

VARIPULSE® MAGNETOPOSITIONING MULTICHANNEL PULSE ABLATION CATHETER

VARIPULSE® magnetic positioning multi-channel pulse ablation catheter is currently the leading technology in the field of atrial fibrillation ablation worldwide, using high-voltage short-term electrical pulse technology to lead to irreversible electroporation of the cell membrane, which eventually leads to apoptosis, thereby helping patients treat atrial fibrillation
.
This product will help doctors to ablate according to the treatment strategy of each patient with atrial fibrillation to better serve the patient
.

Sanofi: Dapital ® (dupilumab injection)

This year is the fifth time that Dabito ® has appeared
on the stage of the Expo.
As the first targeted biological agent for the treatment of moderate to severe atopic dermatitis, it can target the core and key driving factors of atopic dermatitis, interleukin 4 (IL-4) and interleukin 13 (IL-13), block the type 2 inflammatory pathway in the pathology and development of atopic dermatitis, and effectively inhibit the type 2 inflammatory response, thereby treating atopic dermatitis
.

In July of this year, Dabito ® was nominated
for the 2022 Galen Award for "Best Biotechnology Product Award".
The Galen Prize, known as the "Nobel Prize in the pharmaceutical world", is the highest honor recognized by the pharmaceutical and biomedical industry to recognize outstanding new drug discoveries and is the highest honor
in the field of drug research and development.

Sanofi vaccine: Beyfortus (nirsevimab)

The Sanofi vaccine brings Beyfortus, the world's first and only widely available respiratory syncytial virus (RSV) prevention method for infants, which provides sustained protection
for infants throughout the RSV epidemic season with just one injection.
This is also the product's debut in China, and it has been awarded the "Breakthrough Therapy Program"
by the National Center for Drug Evaluation (CDE) of China.

RSV is the most common cause of lower respiratory tract infections in infants, including bronchiolitis and pneumonia
.
RSV is also the leading cause of infant hospitalizations worldwide, and the majority of hospitalizations occur in healthy term infants
.
At present, there is no RSV prevention method in China, and the treatment is limited to relieving symptoms
.